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Summary
 
1
 
a
 
,25-dihydroxyvitamin D
 
3
 
 (D
 
3
 
) promotes the maturation of myeloid cells and surface expres-
sions of CD14 and CD11b, markers of cell differentiation in response to D
 
3
 
. To examine how
these responses are regulated, THP-1 cells were grown in serum-free medium and incubated
with D
 
3
 
. This was associated with rapid and transient increases in phosphatidylinositol 3-kinase
(PI 3-kinase) activity. Furthermore, induction of CD14 expression in response to D
 
3
 
 was abro-
gated by (a) the PI 3-kinase inhibitors LY294002 and wortmannin; (b) antisense oligonucle-
otides to mRNA for the p110 catalytic subunit of PI 3-kinase; and (c) a dominant negative
mutant of PI 3-kinase. In THP-1 cells, induction of CD11b expression by D
 
3
 
 was also abro-
gated by LY294002 and wortmannin. Similarly, LY294002 and wortmannin inhibited D
 
3
 
-
induced expression of both CD14 and CD11b in peripheral blood monocytes. In contrast to
CD14 and CD11b, hormone-induced expression of the Cdk inhibitor p21 in THP-1 cells was
unaffected by either wortmannin or LY294002. These findings suggest that PI 3-kinase selec-
tively regulates D
 
3
 
-induced monocyte differentiation, independent of any effects on p21.
Pretreatment of THP-1 cells with antisense oligonucleotides to the vitamin D receptor
(VDR) mRNA abrogated both activation of PI 3-kinase in response to D
 
3
 
 and hormone-
induced CD14 expression. Moreover, both Western blots and in vitro kinase assays carried out
on immunoprecipitates of the VDR showed that D
 
3
 
 treatment brought about formation of a
complex containing both PI 3-kinase and the VDR. These findings reveal a novel, nonge-
nomic mechanism of hormone action regulating monocyte differentiation, in which vitamin
D
 
3
 
 activates a VDR- and PI 3-kinase–dependent signaling pathway.
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T
 
he steroid hormone 1
 
a
 
,25-dihydroxyvitamin D3
(D
 
3
 
)
 
1
 
 plays critical roles in regulating numerous cellu-
lar and physiological responses. In addition to its well-
established importance in plasma calcium homeostasis (1, 2)
and bone resorption (3, 4), D
 
3
 
 also plays a functional role in
the hemopoietic system. D
 
3
 
 modulates the expression of
several genes in promonocytic cell lines, thereby regulating
their differentiation (5). Indeed, when myeloid leukemia
cells such as HL60, U937, THP-1, and M1 are incubated
with D
 
3
 
, they differentiate into cells expressing functional
properties and differentiation markers of monocytes and/or
macrophages, including CD14 and CR3 (6–9).
The pleiotropic effects of D
 
3
 
 are principally mediated
through the intracellular vitamin D receptor (VDR). The
VDR is a member of the superfamily of nuclear steroid,
thyroid, and retinoic acid receptors. As such, it functions as
a ligand-dependent transcription factor, regulating the acti-
vation of vitamin D–responsive target genes (10). At the
molecular level, the VDR activates its target genes via in-
 
1
 
Abbreviations used in this paper:
 
 D
 
3
 
, 1
 
a
 
,25-dihydroxyvitamin D
 
3
 
; ECL, en-
hanced chemiluminescence; IGF, insulin-like growth factor; MAP, mito-
gen-activated protein; MFI, mean fluorescence intensity; PI 3-kinase, phos-
phatidylinositol 3-kinase; PIP, phosphatidylinositol 3-phosphate; RT,
reverse transcription; S-oligo, phosphorothioate-modified oligonucleotide;
VDR, vitamin D receptor; VDRE, vitamin D–responsive element. 
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teractions with specific DNA sequences designated as vita-
min D–responsive elements (VDRE) (11–13), a mode of
signaling referred to as “genomic action.”
CD14 is a 55-kD glycoprotein originally described as a
differentiation marker of monocytes (14). Extensive re-
search has demonstrated that CD14 is involved in mediat-
ing responses to several bacterial cell wall products, most
notably bacterial LPS (15–18). CD14 has other pleiotropic
effects including, but not limited to, regulating IL-2–induced
monocyte tumoricidal activity (19), monocyte resistance to
HIV (20), and the adhesive capacity of the molecule LFA-1
(21, 22). As CD14 is inserted into the cell membrane through
a glycosylphosphatidylinositol anchor (23), the mode of sig-
nal transduction through this molecule has been intensively
investigated. Recent reports indicate a 
 
Drosophila
 
 Toll–like
membrane protein acts as a cell surface coreceptor to medi-
ate signaling after ligand binding to CD14 (24, 25).
CD14 is undetectable on the surface of monocytic pre-
cursors, and increases dramatically during their differentia-
tion into monocytes (26–28). Therefore, surface expression
of CD14 is an excellent model in which to study the
mechanisms of myeloid cell maturation regulated by D
 
3
 
.
Induction of CD14 expression in response to D
 
3
 
 occurs at
the level of gene transcription and requires new protein
synthesis (28, 29). However, a curious paradox of this and
other systems is that VDRE sequences have not been iden-
tified in the promoter regions of many D
 
3
 
-inducible genes,
including CD14 (10, 28). Hence, the regulatory events
leading to CD14 expression in response to D
 
3
 
 remain
largely unknown.
The 
 
b
 
2
 
 integrin CR3 is another classical marker of
monocyte differentiation that is involved in cell adhesion
and also functions as a complement receptor (6–9). CD11b,
the 
 
a
 
 subunit of CR3, is a 160-kD glycoprotein that asso-
ciates noncovalently with a 
 
b
 
2
 
 subunit partner, CD18.
CD11b–CD18 is expressed by mature myeloid cells, and is
widely used as an early monocyte differentiation marker
(30). Vitamin D
 
3
 
 has been shown to increase cell surface
expression of CD11b by HL-60 (30, 31), U937 (31), and
THP-1 cells (8).
In various attempts to define the molecular mechanisms
regulating cellular responses to D
 
3
 
, efforts have been made
to identify alternative signaling pathways to the classical
mode of genomic action. Indeed, during the past decade,
experimental evidence for “nongenomic” signaling has
challenged the concept of exclusive VDR-mediated ge-
nomic action. For example, D
 
3
 
 has been shown to stimu-
late the rapid formation of second messengers including
ceramides, cAMP, inositols, and calcium, and to activate a
variety of protein kinases including protein kinase C, Raf,
mitogen-activated protein (MAP) kinase, and Src family
kinases (10, 32–34). However, the physiological impor-
tance of nongenomic signaling by itself or relative to
VDR-mediated genomic action is still unclear. Moreover,
it is not known whether D
 
3
 
 uses the classical VDR for
nongenomic signaling, or whether an alternative receptor
system is involved.
Phosphatidylinositol 3-kinase (PI 3-kinase), a lipid kinase
 
composed of a Src homology 2 domain–containing regula-
tory subunit (p85) and a 110-kD catalytic subunit (p110),
catalyzes the formation of inositol phospholipids phosphor-
ylated at the D3 position of PI. Although PI 3-kinase is
known to be important in a wide variety of cellular pro-
cesses, including intracellular trafficking, organization of
the cytoskeleton, cell growth and transformation, and pre-
vention of apoptosis (35, 36), its potential role in D
 
3
 
-induced
monocyte differentiation remains largely unknown. In this
regard, in a recent series of experiments from this labora-
tory that examined monocyte differentiation, it was ob-
served that expression of a dominant negative mutant of PI
3-kinase in U937 cells abrogated D
 
3
 
-induced CD14 ex-
pression (Herrera-Velit, P., Z. Hmama, and N. Reiner,
unpublished data). This finding provided direct evidence to
suggest that monocyte differentiation in response to D
 
3
 
may be PI 3-kinase dependent. This study investigated the
role of PI 3-kinase and the VDR in regulating monocyte
differentiation in response to D
 
3
 
. The results obtained show
that D
 
3
 
-induced expression of the monocyte differentiation
markers CD14 and CD11b requires PI 3-kinase, and that
hormone treatment induces formation of a signaling com-
plex in which the VDR associates with PI 3-kinase. Acti-
vation of PI 3-kinase represents a novel pathway for D
 
3
 
 sig-
naling regulating monocyte differentiation, and suggests a
mechanism of action for the VDR distinct from classical
genomic signaling.
 
Materials and Methods
 
Reagents and Chemicals.
 
RPMI 1640, HBSS, and penicillin/
streptomycin were from StemCell Technologies, Inc. Wortman-
nin, 
 
l
 
-
 
a
 
-phosphatidylinositol, PMSF, leupeptin, pepstatin A, and
aprotinin were purchased from Sigma Chemical Co. LY294002
and microcystin were from Calbiochem Corp. Protein A–agarose
and electrophoresis reagents were purchased from Bio-Rad Lab-
oratories. [
 
g
 
-
 
32
 
P]ATP was from Nycomed Amersham Plc.
 
mAbs.
 
The following mAbs were used: 3C10 (mouse IgG2b,
anti-CD14 mAb; a gift from Dr. W.C. Van Voorhis, University
of Washington, Seattle, WA); W6/32 (mouse IgG
 
2a
 
, anti–HLA
class I mAb; American Type Culture Collection); UB93-3 (mouse
mAb to PI 3-kinase; Upstate Biotechnology Inc.) and 9A7 (rat
IgG
 
2b
 
, anti-VDR; Chemicon International). Other Abs used in-
cluded anti-CD14 and anti-CD11b, both murine IgG
 
1
 
 (SC-7328
and SC-1186, respectively; Santa Cruz Biotechnology, Inc.). Mu-
rine IgG
 
1
 
 isotype control MG100 was from Caltag Laboratories.
 
Cell Lines.
 
The promonocytic cell line THP-1 was from the
American Type Culture Collection. The promonocytic cell line
U937 transfected with cDNA, encoding the entire coding region
of either wild-type bovine PI 3-kinase subunit p85
 
a
 
 (Wp85
 
a
 
) or
mutant bovine p85
 
a
 
, (
 
D
 
p85
 
a
 
) has been described (37). The mu-
tant has a deletion of 35 amino acids from residues 479–513 of
bovine p85
 
a
 
 and the insertion of two other amino acids (Ser-
Arg) in the deleted position. Mutant p85
 
a
 
 competes with native
p85 for binding to essential signaling proteins, thereby acting as a
dominant negative mutant (38). THP-1 and U937 cell lines were
cultured in RPMI 1640 supplemented with 10% FCS (Hy-
Clone), 2 mM 
 
l
 
-glutamine, penicillin (100 U/ml), and strepto-
mycin (100 
 
m
 
g/ml). Cell density was maintained at a concentra-
tion of 
 
,
 
5 
 
3
 
 10
 
5
 
/ml. 
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Isolation and Culture of Human Monocytes.
 
Peripheral blood mono-
nuclear cells were isolated as described previously (39). Mono-
cytes were allowed to adhere for 1 h at 37
 
8
 
C in a humidified
atmosphere with 5% CO
 
2
 
. Nonadherent cells were removed by
three washes with HBSS. Adherent cells were immediately
treated and used for cell surface phenotype analysis.
 
Cell Surface Phenotype Analysis.
 
To measure the expression of
surface molecules, cells were incubated with specific mouse mAb
or irrelevant isotype-matched IgG (10 
 
m
 
g/ml) for 30 min, then
washed twice and labeled with FITC-conjugated F(ab
 
9
 
)
 
2
 
 sheep
anti–mouse IgG (Sigma Chemical Co.) for 30 min. Cells were
then washed twice and fixed in 2% paraformaldehyde in staining
buffer. All staining and washing procedures were performed at
4
 
8
 
C in HBSS containing 0.1% NaN
 
3
 
 and 1% FCS. Cell fluores-
cence was analyzed using a Coulter Elite flow cytometer. Rela-
tive fluorescence intensities of 5,000–10,000 cells were recorded
as single-parameter histograms (log scale, 1,024 channels, 4 log
decades), and the mean fluorescence intensity (MFI) was calcu-
lated for each histogram. Results are expressed as MFI indices
which correspond to MFI of cells 
 
1
 
 specific Ab/MFI of cells 
 
1
 
irrelevant isotype-matched IgG.
 
In Vitro PI 3-Kinase Assay.
 
Cell lysates for analysis of PI
3-kinase were prepared in 20 mM Tris, pH 8.0, 1% Triton X-100,
137 mM NaCl, 10% glycerol, 2 mM EDTA, 1 mM Na
 
3
 
VO
 
4
 
, 5
mM NaF, 100 nM microcystin, 1 mM PMSF, 10 
 
m
 
g/ml leupep-
tin, 10 
 
m
 
g/ml pepstatin, and 10 
 
m
 
g/ml aprotinin. Aliquots of ly-
sates adjusted for protein concentration (300–500 
 
m
 
g protein)
were incubated for 2–4 h at 4
 
8
 
C with UB93-3 mAb (anti–PI
3-kinase), and immune complexes were adsorbed onto protein
A–agarose for 30–60 min. The complexes were washed twice
with lysis buffer and three times with 10 mM Tris-HCl, pH 7.4.
PI 3-kinase activity was measured as described (22, 40). In brief,
immunoprecipitates were incubated for 10 min at 4
 
8
 
C with 10
 
m
 
g of sonicated (3 times for 20 s in an ultrasonic cell disrupter;
Branson Sonic Power Co.) 
 
l
 
-
 
a
 
-phosphatidylinositol in 10 
 
m
 
l of
30 mM Hepes, to which was added 40 
 
m
 
l of kinase assay buffer
(30 mM Hepes, 30 mM MgCl
 
2
 
, 200 
 
m
 
M adenosine, 50 
 
m
 
M
ATP, and 10 
 
m
 
Ci of [
 
g
 
-
 
32
 
P]ATP). Reactions were carried out for
15 min at room temperature, and stopped by the addition of 100
 
m
 
l of 1 N HCl and 200 
 
m
 
l of chloroform/methanol (1:1, vol/
vol). Lipids were separated on oxalate-treated silica TLC plates
using a solvent system of chloroform/methanol/water/28% am-
monia (45:35:7.5:2.5, vol/vol/vol/vol). Plates were exposed to
X-ray film at 
 
2
 
70
 
8
 
C. Incorporation of radioactivity into lipids
was measured by excising the corresponding portions of the TLC
plate, followed by liquid scintillation counting. Alternatively, cell
lysates were incubated overnight at 4
 
8
 
C with 9A7 mAb (anti-
VDR), and immune complexes were adsorbed onto protein
A–agarose, washed in lysis buffer containing 200 mM NaCl, and
assayed for PI 3-kinase activity as described above.
 
RNA Isolation and Reverse Transcription PCR. RNA isolation,
cDNA synthesis, and PCR conditions were as described previously
(41). Sequences (59 to 39) of oligonucleotide primers used in PCR
amplifications were as follows: CD14 sense, CCC AAG CTT GGG
CAG AGG TTC GGA AGA CTT ATC G; CD14 antisense, GGG
GTA CCC CTT GAC CGT GTC AGC ATA CTG CC (29);
Cdk inhibitor p21 sense, TTC TCC TTT TCC TCT CTC C; p21
antisense, TCT ACT CCC CCA TCA TAT ACC; b-actin sense,
CAC CCC GTG CTG CTG ACC GAG GCC; b-actin antisense,
CCA CAC GGA GTA CTT GCG CTC AGG (41). Controls in-
cluded in the reverse transcription (RT)-PCR reactions were no
RNA and RNA without RT, and different cycle numbers of PCR
reactions were performed to ensure linear cDNA amplification.
Sense and Antisense Oligonucleotides. Phosphorothioate-modi-
fied oligonucleotides (S-oligos) to VDR and p110 subunit of PI
3-kinase were synthesized by Life Technologies, Inc. The oligo-
nucleotides were phosphorothioate-modified to limit intracellular
degradation, and purified by high-performance liquid chroma-
tography to remove incomplete synthesis products. 21-mer se-
quences, including the presumed translation initiation site of hu-
man cDNA sequences corresponding to the VDR (42) and the a
isoform of the p110 subunit of PI 3-kinase (43), were made in
both sense and antisense orientations with the following se-
quences: VDR sense, 59-ATG GAG GCA ATG GCG GCC
AGC-39; VDR antisense, 59-GCT GGC CGC CAT TGC CTC
CAT-39; p110 sense, 59-ATG CCT CCA AGA CCA TCA
TCA-39; and p110 antisense, 59-TGA TGA TGG TCT TGG
AGG CAT-39. The sequences were selected by screening for
uniqueness using Blast 227, and were also tested for lack of sec-
ondary structure and pairing by using Primer Software (v. 2.0).
3–7 3 106 THP-1 cells were suspended in 500 ml RPMI con-
taining 2.5% lipofectAMINE (Life Technologies, Inc.) and 5 mM
S-oligo, and incubated on a rotary shaker for 4 h at 378C. In ad-
dition, fluorescent-modified antisense and sense and flow cytom-
etry were used to monitor S-oligo incorporation into cells. After
this incubation, the medium was brought up to 5–10 ml, and
cells were cultured for an additional 18 h at 378C and 5% CO2.
Immunoprecipitation and Western Blotting. To examine a po-
tential association between the VDR and PI 3-kinase, D3-treated
cells were lysed in the buffer used to prepare cell lysates for PI
3-kinase assay, then immunoprecipitated with specific mAb to
VDR. Immunoprecipitates were washed with lysis buffer con-
taining 200 mM NaCl to minimize nonspecific protein–protein
interactions. Samples were then analyzed by SDS-PAGE and im-
munoblotting with Abs to the p85 PI 3-kinase subunit as de-
scribed previously (40). To measure the effects of cell treatments
with antisense S-oligos on protein levels of VDR, whole-cell ly-
sates prepared by boiling in Laemmli buffer were subjected to
SDS-PAGE and immunoblotting with the mAb 9A7. Mem-
branes were developed by enhanced chemiluminescence (ECL)
as described (44).
Results
D3-induced CD14 Expression in THP-1 Cells. Initial ex-
periments involving immunofluorescence and flow cyto-
metric analysis defined the experimental conditions for D3-
induced CD14 expression by THP-1 cells. THP-1 cells
maintained in complete medium expressed nearly unde-
tectable levels of CD14 on the surface, and treatment with
hormone caused a dose- and time-dependent increase in
CD14 expression (Fig. 1). A response was obtained in the
presence of as little as 0.1 nM D3 (Fig. 1 A), and at 100 nM,
virtually all cells expressed CD14 at an z50-fold increase
in MFI. The kinetics of induction of CD14 in response to
100 nM D3 is shown in Fig. 1 B. CD14 expression in-
creased progressively with time and was maximal (55-fold
increase in MFI index, average of 2 separate experiments)
after 48 h. Since a 24-h exposure to 100 nM D3 was suffi-
cient to induce a high level of surface CD14 (53-fold in-
crease in MFI index, average of 2 separate experiments) in
nearly 100% of cells, subsequent experiments were carried
out under these conditions.1586 Vitamin D3, PI 3-Kinase, and Myeloid Cell Differentiation
Other experiments examined whether the CD14 re-
sponse of cells to D3 (100 nM, 24 h) was serum dependent.
Results obtained in three independent experiments (Fig. 1
C) using RPMI 1640 alone showed that THP-1 cells were
fully responsive for CD14 induction (MFI index 5 104.4 6
5.1, mean 6 SEM). Addition of FCS had only a limited
additive effect (MFI index 5 125.0 6 14.1). Conversely,
addition of insulin growth factor (IGF)-I a serum compo-
nent known to influence cell differentiation (30), to D3
minimally inhibited CD14 expression. These observations
suggest that in THP-1 cells, D3 is capable of inducing
CD14 in the absence of any serum factors, and that D3 de-
livery to cell surface is independent of serum vitamin D
binding protein (45, 46).
Treatment of THP-1 Cells with D3 Activates PI 3-Kinase.
In light of the important roles played by PI 3-kinase in reg-
ulating the differentiation of a variety of cell types (47–49),
the possibility that D3-induced monocytic differentiation
involves PI 3-kinase was investigated. As shown in Fig. 2
A, incubation of serum-starved THP-1 cells with 10 nM
D3 brought about a significant increase in PI 3-kinase activ-
ity (3.07 6 1.17 fold increase, mean 6 SEM, n 5 3), with
a maximum response observed at 1 mM (6.59 6 1.47 fold
increase). Although PI 3-kinase activity was also signifi-
cantly increased in IGF-I (100 ng/ml)–treated cells (Fig. 2
A), this was not associated with increased CD14 expression
(Fig. 1 C). Time course experiments using 100 nM D3
(Fig. 2 B) showed that PI 3-kinase activation was detect-
able by as early as 5 min and reached a maximum level
(4.94 6 0.72 fold increase) by 20 min.
D3-induced Expression of CD14 and CD11b are PI 3-Kinase
Dependent. To address whether PI 3-kinase activation is
required for D3-induced monocyte differentiation, serum-
starved THP-1 cells were incubated with either wortman-
nin or LY294002 for 20 min before addition of hormone.
Inhibitors were used at concentrations known to be rela-
tively selective for inhibition of PI 3-kinase (48, 50). Incu-
bation with inhibitors alone had no effect on basal expres-
sion of CD14 (data not shown). Preincubation with 5 nM
wortmannin led to 65.7 6 5.6% inhibition of D3-induced
CD14 expression (mean 6 SEM, n 5 3; Fig. 3 A). Increas-
ing the concentration of wortmannin to 50 nM inhibited
CD14 expression by 86.0 6 8.5%. LY294002, an inhibitor
of PI 3-kinase that acts via a distinct mechanism from that
Figure 1. Induction of CD14
expression in response to D3. (A)
THP-1 cells were incubated in
RPMI 1640 containing 10% FCS
for 24 h with the indicated con-
centrations of D3. (B) Cells were
incubated in the same medium
with 100 nM D3 for the indi-
cated times. (C) Serum-starved cells were incubated for 24 h either in serum-free
medium, or in medium supplemented with either 10% FCS, IGF-I (100 ng/ml), D3
(100 nM), 10% FCS 1 D3, or IGF-I 1 D3. At the end of incubation, cells were
washed with staining buffer and labeled for 30 min at 48C with either 3C10 (anti-
CD14) mAb or irrelevant IgG2b. Cells were washed and stained with FITC-conju-
gated F(ab)92 sheep anti–mouse IgG. Samples were washed and fixed in 2%
paraformaldehyde before flow cytometric analysis. Results in (A) and (B) are ex-
pressed as histograms of fluorescence intensity. Histograms displaced to the right rep-
resent cells stained with 3C10, and histograms on the left represent cells stained with
irrelevant IgG2b. Data presented correspond to one of two independent experiments
yielding similar results. In C, results are means 6 SEM (n 5 3 independent experi-
ments) of MFI indices which correspond to the following ratio: MFI of cells incu-
bated with specific Ab/MFI of cells stained with irrelevant Ab.
Figure 2. D3 induces PI 3-kinase activation in THP-1 cells. Serum-starved
(6 h) cells were stimulated with D3, followed by detergent lysis and immuno-
precipitation with anti–PI 3-kinase Ab. PI 3-kinase activity was assayed as de-
scribed in Materials and Methods. Spots corresponding to phosphatidylinosi-
tol 3-phosphate (PIP) were cut and subjected to scintillation counting. In A,
cells were stimulated with a range of concentrations of D3 (0–1,000 nM) or
with IGF-I (100 ng/ml) for 20 min. In B, cells were stimulated with 100 nM
D3 for 0–60 min. The upper rectangles in both panels show PIP spots ob-
tained in one representative experiment. The graphical data shown are the
means 6 SEM of values obtained in three separate experiments. Activities are
expressed as fold increase relative to control (untreated) cells.1587 Hmama et al.
of wortmannin, when used at 1.5 mM reduced D3-induced
CD14 expression by 66.8 6 11.9%. CD14 expression de-
creased further in the presence of 15 mM LY294002 (88.1 6
5.1%). In contrast to abrogation of D3-induced CD14,
neither wortmannin nor LY294002 had significant effects
on the expression of HLA class I molecules (data not
shown), indicating that the effects of neither wortmannin
nor LY294002 were due to nonspecific toxicity. The PI
3-kinase inhibitors LY294002 and wortmannin also attenu-
ated D3-induced cell surface expression of CD11b by
THP-1 cells. While incubation with inhibitors alone had
no effect on basal levels of CD11b expression, preincuba-
tion with 5 nM wortmannin inhibited the response to D3
by 41 6 7% (Table I). A higher concentration of 50 nM
increased inhibition to 100 6 12%. LY294002 inhibited
D3-induced CD11b surface expression by 48 6 10% at a
concentration of 1.5 mM, and by 88 6 14% at a concentra-
tion of 15 mM (Table I). Surface expression of CD14 and
CD11b was also examined in human peripheral blood mono-
cytes. As shown in Table II, LY294002 and wortmannin
markedly inhibited D3-induced expression of both CD14 and
CD11b in these cells.
Figure 3. Wortmannin and LY294002 attenuate D3-induced CD14 expression, but not expression of Cdk inhibitor p21. Serum-starved THP-1 (4 3
106) cells were incubated for 20 min at 378C and 5% CO2 in medium alone, with wortmannin (Wrtm), or with LY294002 (LY). D3 (100 nM) was then
added for 24 h at 378C. (A) Aliquots of cells (z0.5 3 106) from each treatment were washed with staining buffer and labeled with anti-CD14 mAb or ir-
relevant mAb, followed by FITC-conjugated secondary Abs. Flow cytometric analyses were performed, and MFI indices were determined as described in
the legend to Fig. 1. The results shown are the means 6 SEM of values obtained in three separate experiments. (B and C) Total RNA was extracted from
the cells remaining, and RT-PCR was carried out for CD14 (B) and p21 (C) as described (reference 41). b-actin was analyzed to control for loading.
Negative controls consisting of no RNA and RNA without RT were included, and these produced no signals (data not shown). The data shown are
from one of two independent experiments that yielded similar results.
Table I. Effects of PI 3-Kinase Inhibitors on Vitamin D3–induced 
Surface Expression of CD11b by THP-1 Cells
Treatment CD11b (MFI index)
Control 1.19 6 0.17
Vit D3 2.77 6 0.78
15 mM LY alone 1.17 6 0.17
50 nM wrtm alone 1.13 6 0.15
1.5 mM LY 1 vit D3 2.01 6 0.41
5.0 nM wrtm 1 vit D3 2.13 6 0.37
15 mM LY 1 vit D3 1.38 6 0.22
50 nM wrtm 1 vit D3 1.19 6 0.14
Serum-starved THP-1 cells were incubated for 20 min at 37°C and 5%
CO2 in either medium alone, wortmannin (wrtm), or LY294002 (LY).
D3 (vit D3 [100 nM]) was then added for 24 h at 37°C. Cells from each
treatment were washed with staining buffer, labeled with anti-CD11b
mAb or irrelevant mAb followed by FITC-conjugated secondary Abs,
and flow cytometric analyses were performed. The results shown are the
means 6 SEM of values obtained in three separate experiments. Results
are expressed as MFI indices which correspond to MFI of cells 1 specific
Ab/MFI of cells 1 irrelevant isotype-matched IgG.
Table II. Effects of PI 3-kinase Inhibitors on Vitamin D3–induced 
Surface Expression of CD14 and CD11b by Peripheral Blood Monocytes
Treatment
CD14 (MFI
index)
CD11b (MFI
index)
Control 1.09 1.27
Vit D3 1.98 1.80
15 mM LY alone 1.03 1.08
50 nM wrtm alone 1.21 1.25
1.5 mM LY 1 vit D3 1.37 1.63
5.0 nM wrtm 1 vit D3 1.54 1.54
15 mM LY 1 vit D3 1.07 1.24
50 nM wrtm 1 vit D3 1.20 1.20
Peripheral blood monocytes were allowed to adhere to plastic dishes
for 1 h at 37°C and 5% CO2 in serum-free medium. Cells were then
washed with warm HBSS, and the remaining adherent monocytes were
incubated for 20 min at 37°C and 5% CO2 in either medium alone,
wortmannin (wrtm), or LY294002 (LY). D3 (vit D3 [100 nM]) was
then added for 24 h at 37°C. Cells from each treatment were washed
with staining buffer and labeled with either anti-CD14 mAb, anti-
CD11b mAb, or irrelevant mAb, followed by FITC-conjugated sec-
ondary Abs. Flow cytometric analyses were performed, and MFI indi-
ces were determined as described in Materials and Methods. Results are
expressed as MFI indices which correspond to MFI of cells 1 specific
Ab/MFI of cells 1 irrelevant isotype-matched IgG. The results shown
are based on 10,000 recorded events for each treatment condition per-
formed on cells from 1 individual donor.1588 Vitamin D3, PI 3-Kinase, and Myeloid Cell Differentiation
Inhibition of PI 3-kinase has been shown to affect the
transport of some cell surface molecules (51), and thus was
a possible mechanism to explain the effects of PI 3-kinase
inhibitors on D3-induced CD14 expression. However,
when total RNA was isolated and RT-PCR was per-
formed using primers for CD14 and b-actin, the results
showed that mRNA levels for CD14 were markedly reduced
in cells incubated with either wortmannin or LY294002 (Fig.
3 B). These findings indicate that inhibition of PI 3-kinase
results in attenuation of D3-induced CD14 gene expression
at a pretranslational level.
Treatment of immature myeloid cells with D3 induces
the expression of the Cdk inhibitor p21, and the latter has
been shown to regulate gene expression and to promote
myleoid cell differentiation (52). Experiments were carried
out to examine whether the induction of p21 in response
to hormone also involved PI 3-kinase. As shown in Fig. 3
C, THP-1 cells expressed low levels of p21 mRNA in the
basal state. As expected, p21 expression was significantly
induced in response to incubation of cells with D3. How-
ever, in contrast to the findings with CD14 and CD11b,
preincubation of cells with either wortmannin or LY294002
had no effect on hormone-induced expression of p21. These
findings suggest that PI 3-kinase selectively regulates mono-
cyte differentiation, independent of any effects on p21.
The role of PI 3-kinase in regulating monocyte differen-
tiation was investigated further by inhibiting the synthesis
of the p110 catalytic subunit of PI 3-kinase. THP-1 cells
were incubated in the presence of antisense S-oligo com-
plementary to the p110 translation initiation region (in-
cluding the ATG initiation codon), and then assayed for
both PI 3-kinase activation and CD14 expression in re-
sponse to D3. Flow cytometric analysis of cells exposed to
fluorescein-modified antisense S-oligo, under the same
conditions used for unmodified S-oligos, revealed that
THP-1 cells readily incorporated foreign DNA (data not
shown). As shown in Fig. 4 A, antisense S-oligo to p110
mRNA significantly attenuated D3-induced PI 3-kinase ac-
tivity (% inhibition 5 87.1 6 5.6, mean 6 SEM, n 5 3),
whereas at the same concentration, the control sense S-oligo
had no apparent effect on the PI 3-kinase response. In
parallel with this effect on PI 3-kinase activation, pretreat-
ment with antisense S-oligo (and not with the control,
sense oligo) almost completely inhibited hormone-induced
surface expression of CD14 (% inhibition 5 91.7 6 3.9,
mean 6 SEM of three experiments; Fig. 4 B). In addition,
RT-PCR results shown in Fig. 4 C demonstrated that D3-
induced mRNA levels for CD14 were markedly diminished
in cells treated with antisense S-oligo to p110 mRNA.
The PI 3-kinase requirement for D3-induced CD14 ex-
pression was also examined in U937 cells transfected with a
dominant negative mutant of p85 (Dp85). Stable transfec-
tion of these cells with Dp85 resulted in a significant reduc-
tion of stimulated PI 3-kinase activity (22, 37). Exposure of
Dp85 U937 to D3 (100 nM, 48 h) led to only a marginal
increase in surface expression of CD14 above baseline. In
contrast, cells transfected with wild-type p85 showed sig-
nificant induction of CD14 expression (Fig. 5 A). In addi-
tion, as observed with THP-1 cells, RT-PCR experiments
showed that attenuation of PI 3-kinase in U937 cells re-
sulted in markedly reduced response to D3 for induction of
CD14 mRNA (Fig. 5 B). Taken together, these findings
Figure 4. Antisense S-oligo to
the p110 subunit of PI 3-kinase in-
hibits D3-induced CD14 expres-
sion. 7 3 106 THP-1 cells were
suspended in 500 ml of 2.5% lipo-
fectAMINE/RPMI 1640 alone
(Control), or containing 5 mM of
either sense (S) or antisense (AS)
S-oligo to p110. Cells were then
incubated on a rotary shaker for
4 h at 378C. The incubation was
brought up to 10 ml of medium,
and cells were cultured for an addi-
tional 18 h at 378C and 5% CO2.
(A) 3 3 106 cells were stimulated
with 100 nM D3 for 20 min and
assayed for PI 3-kinase assay as de-
scribed in Materials and Methods. The upper rectangle shows PIP spots obtained in one repre-
sentative experiment. The graphical data shown below represent PI 3-kinase activities (means 6
SEM of values obtained in three separate experiments), calculated as described in the legend to
Fig. 2. (B) Fractions of control or S-oligo–treated cells (z1 3 106) were incubated in medium
alone or with D3 (100 nM, 24 h), washed with staining buffer, and then labeled with anti-CD14
mAb or irrelevant mAb, followed by FITC-conjugated secondary Abs. Flow cytometric analyses
were performed, and MFI indices were determined as described in the legend to Fig. 1. Results
are expressed as histograms of fluorescence intensity. Histograms displaced to the right represent
cells stained with anti-CD14, and histograms on the left represent cells stained with irrelevant
IgG2b. Bold, italicized values are means 6 SEM (n 5 3) of MFI indices, calculated as described
in the legend to Fig. 1. (C) Control or S-oligo–treated cells (z3 3 106) were incubated with D3
(100 nM, 24 h). Total RNA was extracted and RT-PCR was carried out for CD14 and b-actin
as described (reference 41). RT-PCR controls, as described in the legend to Fig. 3, were in-
cluded. The data shown are from one of two independent experiments that yielded similar results.1589 Hmama et al.
strongly suggest that PI 3-kinase plays a central role in
D3-induced monocyte differentiation, and indicate that PI
3-kinase activation is required to induce CD14 expression.
Induction of CD14 in Response to D3 Requires the VDR.
Many responses to D3, such as induction of expression of
osteopontin, osteocalcin, calbindin, and 24-hydroxylase,
are brought about by a mechanism involving binding of the
VDR to a specific VDRE in the corresponding promoters
(53). Since no VDRE has been identified within the CD14
gene promoter (28), this raised the question as to whether
the VDR plays any role in regulating D3-induced CD14
expression. To address this question, THP-1 cells were in-
cubated overnight with antisense S-oligo specific to VDR
mRNA. This resulted in significant attenuation of the level
of VDR protein in THP-1 cells as detected by Western
blotting (Fig. 6 A). In contrast, pretreatment of cells with
the control, sense S-oligo had no apparent effect on the
level of VDR protein. In parallel with the reduction of VDR
protein, D3-induced surface expression of CD14 was mark-
edly attenuated (Fig. 6 B; in two separate experiments an av-
erage decrease of 86.8% was observed). In addition, cells were
treated with S-oligo antisense specific for VDR mRNA be-
fore D3, followed by RNA extraction and RT-PCR. The
results showed that the induction of CD14 mRNA was
markedly attenuated in antisense-treated cells (Fig. 6 C).
Taken together, these findings strongly suggest that the VDR
is essential for D3-induced CD14 gene expression.
Association of PI 3-Kinase with the VDR. Given the evi-
dence that both PI 3-kinase and the VDR were essential
for induction of CD14 in response to D3, the question ex-
amined next was whether the VDR is required for activa-
tion of PI 3-kinase. THP-1 cells were treated with anti-
sense S-oligos as described above to reduce VDR protein
expression before incubation with D3 (100 nM, 20 min).
Figure 5. CD14 response to
D3 in U937 cells transfected with
wild-type bovine p85a (WP85)
or dominant negative mutant
Dp85a ( Dp85).  (A) Cells were
stimulated with either 100 nM D3
or medium alone for 48 h. Cells
were washed with staining buffer,
and then labeled with anti-CD14
mAb or irrelevant mAb, followed by secondary FITC-conjugated Abs. Flow cytometric analyses
were performed, and MFI indices were determined as described in the legend to Fig. 1. The
data shown are the means 6 SEM of values obtained in three separate experiments. (B) Cells
were stimulated with D3 or medium alone for 24 h, then total RNA was extracted and RT-
PCR was carried out for CD14 and b-actin as described (reference 41). No signals were obtained
with controls consisting of no RNA and RNA without RT (data not shown). The data shown
are from one of two independent experiments that yielded similar results.
Figure 6. VDR antisense S-oligo inhibits D3-induced CD14 expression. 5 3 106 THP-1 cells were suspended in 500 ml of 2.5% lipofectAMINE/
RPMI 1640 alone (control), or containing 5 mM of either sense (S) or antisense (AS) S-oligo to the VDR. Cells were then incubated on a rotary shaker
for 4 h at 378C. The volume was then brought up to 7 ml, and cells were cultured for an additional 18 h at 378C and 5% CO2. (A) 0.5 3 106 cells were
boiled in Laemmli buffer and subjected to SDS-PAGE and immunoblotting with mAb to VDR. Membranes were developed by ECL as described (ref-
erence 44). The data shown are from one of two independent experiments that yielded similar results. (B) Aliquots of control or S-oligo–treated cells (z1 3
106) were incubated with D3 (100 nM, 24 h), washed with staining buffer, and then labeled with anti-CD14 mAb or irrelevant mAb followed by FITC-
conjugated, secondary Abs. Flow cytometric analyses were performed, and MFI indices were determined as described in the legend to Fig. 1. Results are
expressed as histograms of fluorescence intensity. Histograms displaced to the right represent cells stained with anti-CD14, and histograms on the left rep-
resent cells stained with irrelevant IgG2b. Bold, italicized values in each frame are averages (n 5 2) of MFI indices, determined as in the legend to Fig. 1.
(C) Control or S-oligo–treated cells (z3 3 106) were incubated with D3 (100 nM, 24 h). Total RNA was extracted and RT-PCR was carried out for
CD14 and b-actin as described (reference 41). Controls consisting of no RNA and RNA without RT were included, and no signals were obtained (data
not shown). The data shown are from one of two independent experiments that yielded similar results.1590 Vitamin D3, PI 3-Kinase, and Myeloid Cell Differentiation
Cell lysates were then prepared and assayed for PI 3-kinase
activity. The results in Fig. 7 A show that pretreatment
with antisense to VDR almost completely abrogated
(92.9% inhibition, average of two separate experiments) PI
3-kinase activation in response to D3. In contrast, treatment
with control sense S-oligos to VDR had no inhibitory effect.
The evidence that the D3 receptor was required for both
PI 3-kinase activation and CD14 expression in response to
D3 suggested the possibility that this might involve a signal-
ing complex containing both the VDR and PI 3-kinase. To
test this hypothesis, THP-1 cells were incubated with D3,
and immunoprecipitates prepared with mAb to the VDR
were assayed for PI 3-kinase activity. The results shown in
Fig. 7 B indicate that immunoprecipitates of the VDR pre-
pared from cells activated with D3 contained PI 3-kinase ac-
tivity. To examine further whether the VDR associates with
PI 3-kinase upon D3 stimulation, aliquots from anti-VDR
and anti-p85 (PI 3-kinase) immunoprecipitates of D3-treated
cells were subjected to SDS-PAGE and Western blotting.
Blots were probed with mAb to p85 and developed by ECL.
The results shown in Fig. 7 C indicate that Abs to p85 re-
acted in anti-VDR immunoprecipitates with a band that
presumably corresponds to the p85 subunit of PI 3-kinase.
This association was only observed in cells treated with hor-
mone, and not in untreated cells. Taken together, the find-
ings suggest that D3 treatment induces the formation of a sig-
naling complex containing the VDR and PI 3-kinase. This
results in activation of the lipid kinase, and is required for
monocyte differentiation and induction of CD14 expression.
Discussion
The steroid hormone vitamin D3 is known to induce
immature, myeloid precursor cells to differentiate into ma-
ture monocytic cells. This process is accompanied by high-
level expression of mRNA and protein for CD14, and
other markers such as CD11b (27–29). How these D3-ini-
tiated events are regulated is not completely understood.
Cellular responses to D3 have primarily been attributed to
activation of the VDR, which acts as a transcription factor
modulating the expression of a variety of genes (53). In
contrast to genomic signaling, several reports have impli-
cated alternative, nongenomic mechanisms of action for D3
involving initiation of signaling at the cell membrane (54–
56). The objective of this study was to examine signaling
events in response to D3 in order to define further how this
hormone regulates myeloid cell differentiation.
The principal conclusions drawn from the experiments
reported are that D3-induced expression of CD14 and
CD11b requires both PI 3-kinase and the VDR. More-
over, this process appears to involve the formation of a PI
3-kinase–VDR signaling complex. The conclusion that
D3-induced CD14 expression is PI 3-kinase dependent is
based on several lines of evidence, including: (a) in vitro ki-
nase assays with immunoprecipitated PI 3-kinase, showing
that incubation of cells with D3 leads to activation of the
enzyme (Fig. 2); (b) D3-induced CD14 expression is abro-
gated in THP-1 cells incubated with the PI 3-kinase inhib-
itors, wortmannin and LY294002 (Fig. 3); (c) an antisense
strategy to downregulate PI 3-kinase also attenuated D3-
induced CD14 expression (Fig. 4); and (d) expression of a
dominant negative mutant of PI 3-kinase (Dp85) in U937
cells also completely abrogated D3-induced expression of
both CD14 mRNA and protein (Fig. 5). Similarly, CD11b
induction in response to D3 was also attenuated by wort-
mannin and LY294002 in both THP-1 cells and in human
peripheral blood monocytes. Taken together, these find-
ings establish that D3-induced CD14 and CD11b expres-
Figure 7. The VDR is required for D3-
induced PI 3-kinase activation. (A) 3 3 106
THP-1 cells were treated overnight with 5 mM
of either sense (S) or antisense (AS) S-oligo to
VDR as described in the legend to Fig. 6. Cells
were then stimulated for 20 min with 100 nM
D3, and lysates were prepared and assayed for PI
3-kinase activities as described in Materials and
Methods. The upper rectangle shows PIP spots
obtained in one representative experiment. The
data shown below are PI 3-kinase activities (av-
erages of values obtained in two separate experi-
ments), calculated as described in the legend to
Fig. 2. (B) Cells were stimulated with D3 as in A
and cell lysates were prepared and incubated
overnight at 48C either with 9A7 mAb (anti-
VDR) or with mAb specific for the p85 subunit
of PI 3-kinase. Immune complexes were ad-
sorbed onto protein A and assayed for PI 3-kinase
activities as described in Materials and Methods. The upper rectangle shows PIP
spots obtained in one representative experiment. The data shown below are PI
3-kinase activities (average of two separate experiments), calculated as described in
the legend to Fig. 2. (C) Cell lysates prepared from either control cells or D3-
treated cells were immunoprecipitated with specific mAbs to either the VDR or
the p85 subunit of PI 3-kinase. Immunoprecipitates were then analyzed by SDS-
PAGE and immunoblotting with Abs to p85 (reference 40). Immunoprecipitates
with normal mouse IgG (MIgG) and normal rat IgG (RIgG) were used to control
for the specificity of anti-p85 and anti-VDR Abs, respectively.1591 Hmama et al.
sion are regulated by PI 3-kinase, and that they are consis-
tent with a nongenomic mechanism of hormone action.
Expression of the Cdk inhibitor p21 is induced by D3,
and this is associated with the differentiation of immature
myeloid cells, including the expression of CD14 (52).
Therefore, it was possible that inhibition of PI 3-kinase
may have abrogated hormone-induced expression of p21
proximally, leading to secondary, indirect effects on the ex-
pression of CD14 and CD11b. However, the findings that
neither wortmannin nor LY294002 inhibited the induction
of p21 while at the same time they inhibited the expression
of CD14 and CD11b (Fig. 3, Tables I and II) indicated that
this was not the case. These findings suggest that PI 3-kinase
selectively regulates these monocyte differentiation markers
independent of any effects on p21. They also suggest that
D3-induced signaling initiated through the VDR appears to
involve at least two separate pathways, one leading to p21
induction that is independent of PI 3-kinase, and a second
pathway that is PI 3-kinase dependent and which regulates
at least the induction of CD14 and CD11b. Moreover, al-
though p21 has been shown to be involved in regulating
monocyte differentiation (52), results from the present
study suggest that it is not sufficient by itself for induction of
monocyte differentiation in response to D3, and that other,
PI 3-kinase– and VDR-regulated elements are required.
Induction of CD14 expression in response to D3 is regu-
lated at the level of gene transcription (28, 29) and the
CD14 promoter, particularly from bp 2128 to 270, has
been shown to be critical for CD14 expression in response
to D3 (28). However, this region does not contain a canon-
ical VDRE (28). Rather, the CD14 promoter contains two
GC boxes that bind the nonreceptor, transcription factor
Sp1, and this interaction is believed to be essential for
CD14 expression (28, 57). In light of this molecular data,
activation of CD14 transcription would not be expected to
be a direct response to D3 signaling through the VDR. Nev-
ertheless, experiments that used VDR antisense S-oligo to
downregulate expression of the endogenous VDR before D3
stimulation showed that the VDR is required for D3-induced
expression of CD14 mRNA (Fig. 6). The obligate require-
ment for the VDR in this response was also supported by
the finding that activation of PI 3-kinase in response to
D3 was markedly attenuated in cells treated with VDR anti-
sense (Fig. 7 A). Moreover, a signaling complex containing
both the VDR and PI 3-kinase was identified in D3-treated
cells (Fig. 7, B and C), suggesting that a functional cytosolic
VDR is a prerequisite for PI 3-kinase activation in response
to D3. These findings appear to identify a novel, nongenomic
mechanism of action for the VDR. It is of interest to note
that the hormone-induced formation of a VDR–PI 3-kinase
signaling complex is reminiscent of the finding that activa-
tion of the Raf-MAP kinase pathway by D3 in keratinocytes
involves an association of the VDR with the adaptor pro-
tein p66shc (58). Together, these findings suggest that other
models of nongenomic signaling involving the VDR may
yet be identified.
The observations that PI 3-kinase regulates CD14 ex-
pression in response to D3 and that the VDR is directly in-
volved in this process do not exclude the possibility of a
component of genomic action by the VDR, despite the ab-
sence of a canonical VDRE within the CD14 promoter.
One possibility to consider is that upon incubation of cells
with D3, the VDR may translocate to the nucleus towards
D3-responsive elements, and enhance the activity of the
known CD14 transcription factor Sp1. Two observations
lend support to this hypothesis: (a) the finding of transcrip-
tional synergism between the VDR and Sp1 using a con-
struct of the VDRE, the binding sites for Sp1, and a lu-
ciferase reporter gene (59); and (b) the presence of a
VDRE-like sequence at the distal Sp1 site within the
CD14 gene (60).
The findings that D3-induced monocyte differentiation
for CD14 and CD11b expression requires PI 3-kinase are
consistent with previous reports in which this lipid kinase
has been implicated in regulating the differentiation of var-
ious cell types, including immature myeloid cells (49, 61–
63). For example, indirect data, based solely on the use of
inhibitors, suggested a potential role for PI 3-kinase in reg-
ulating the differentiation of the myeloid leukemia cells
HL-60 (63). In addition, when FDC-P1 myeloid cells that
express the M-CSF receptor c-fms were treated with M-CSF,
there occurred the rapid formation of a complex between
c-fms and several signal transduction proteins, including PI
3-kinase (49). Other studies have suggested that the differ-
entiation of FDC-P1 cells is regulated by the activities of
both phospholipase C-g and PI 3-kinase in response to
M-CSF stimulation (61). In addition, stimulation of type
III receptor tyrosine kinases in the same cell line was ob-
served to lead to PI 3-kinase–dependent monocytic differ-
entiation (62). Thus, the steroid hormone D3 appears to
share with M-CSF the property of PI 3-kinase activation
during the induction of monocyte differentiation.
It is of interest to compare D3 with phorbol esters that
also act to promote monocyte differentiation. For example,
PMA induces the expression of the monocyte differentia-
tion markers CR3 (CD11b/CD18) and p150,95 (64), and
modulates several functional properties of myeloid precur-
sor cells, such as intracellular adhesion molecule 1–depen-
dent adhesion (22), phagocytosis (44, 65), and bactericidal
activity (66). However, PMA does not activate PI 3-kinase
(Hmama, Z., and N. Reiner, unpublished data), and PMA-
induced cell differentiation is resistant to PI 3-kinase inhi-
bition (22). Consistent with the findings presented above,
although low concentrations of D3 induce an z50-fold in-
crease in CD14 surface expression, optimal doses of PMA
resulted in only marginal increases (Hmama, Z., and N.
Reiner, unpublished data). Regarding signaling mecha-
nisms regulating PMA-induced cell differentiation, several
reports have implicated the protein kinase C–Raf-MAP ki-
nase pathway (33, 67, 68). MAP kinase activity has been
also shown to be activated by D3 in keratinocytes, entero-
cytes, and in the promyelocytic cell lines HL60 and NB4
(34, 58, 69). To examine whether the MAP kinase path-
way may be involved in THP-1 cell differentiation, D3-
treated cells were examined for tyrosine phosphorylation of
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kinase activity using myelin basic protein as substrate. The
results obtained (data not shown) indicated that MAP ki-
nase is not activated in response to D3 in THP-1 cells.
The mechanism by which PI 3-kinase becomes activated
in a complex with the VDR is not presently known. At
least one well-established mechanism for activation of PI
3-kinase is known to involve interactions of the Src homol-
ogy 2 domain of the p85 regulatory subunit with tyrosine
phosphorylated proteins, including both receptor- and
nonreceptor-protein tyrosine kinases (35). In the VDR, the
only potential sites of phosphorylation correspond to Ser51
(70) and Ser208 (71), and the relevance of these residues in
VDR-mediated D3 signal transduction is unknown. Thus,
it is not presently clear how a direct interaction of the
VDR with the p85 subunit may lead to activation of PI
3-kinase. On the other hand, a multimolecular complex
involving the VDR and a tyrosine-phosphorylated adaptor
protein could potentially be involved in D3-induced activa-
tion of PI 3-kinase.
At present, it is not clear how VDR-activated PI 3-kinase
would be targeted to the membrane compartment to medi-
ate cellular responses, given the cytosolic and nuclear local-
ization of the VDR. One possibility to consider is that
there is a small, membrane-associated population of VDR
molecules that induces translocation of PI 3-kinase to the
membrane compartment. A second possibility is that once
activated, the kinase may simply diffuse to the vicinity of
the inner leaflet of the plasma membrane. Third, it is also
possible that VDR-activated PI 3-kinase may act on non-
membrane-associated substrates to mediate its effects.
During the course of these studies, it was observed that
IGF-I failed to induce CD14 surface expression (Fig. 1 C),
despite it ability to activate PI 3-kinase (Fig. 2). Therefore,
PI 3-kinase activation in response to D3 appears to be nec-
essary, but not sufficient to bring about CD14 expression.
These findings suggest the possibility that induction of
CD14 in response to D3 may involve VDR-mediated sig-
nals that bifurcate to involve nongenomic effects of PI
3-kinase, perhaps acting in concert with a genomic mecha-
nism of action. In this respect, cross-talk between nuclear
receptor–mediated signaling and nongenomic actions have
been described in D3-treated osteoblasts (72).
In summary, the findings presented demonstrate a novel
pathway in which D3 signaling for myeloid cell differentia-
tion involves PI 3-kinase activation and signal complex forma-
tion with the VDR, which is itself shown to be required for
cell differentiation. This pathway is essential for D3-induced
expression of CD14 and CD11b, and attributes important
functional roles to PI 3-kinase and the VDR in monocyte
differentiation.
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